Bank of New York Mellon Corp Increases Position in Celcuity Inc. (NASDAQ:CELC)

Bank of New York Mellon Corp lifted its stake in Celcuity Inc. (NASDAQ:CELC) by 20.3% in the 4th quarter, HoldingsChannel reports. The fund owned 64,125 shares of the company’s stock after purchasing an additional 10,828 shares during the quarter. Bank of New York Mellon Corp’s holdings in Celcuity were worth $839,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in CELC. State Street Corp raised its holdings in Celcuity by 152.2% in the third quarter. State Street Corp now owns 1,107,415 shares of the company’s stock worth $16,512,000 after purchasing an additional 668,318 shares in the last quarter. Braidwell LP grew its position in shares of Celcuity by 71.2% in the 3rd quarter. Braidwell LP now owns 884,306 shares of the company’s stock worth $13,185,000 after buying an additional 367,663 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Celcuity by 226.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 221,671 shares of the company’s stock worth $3,305,000 after acquiring an additional 153,712 shares in the last quarter. Geode Capital Management LLC lifted its position in Celcuity by 27.6% during the third quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock valued at $9,401,000 after acquiring an additional 136,518 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in Celcuity by 97.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 144,032 shares of the company’s stock valued at $1,885,000 after acquiring an additional 71,006 shares in the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Trading Down 3.0 %

Shares of Celcuity stock opened at $10.51 on Wednesday. The firm’s 50 day simple moving average is $11.24 and its two-hundred day simple moving average is $13.05. The firm has a market capitalization of $390.24 million, a price-to-earnings ratio of -4.03 and a beta of 0.65. Celcuity Inc. has a 12-month low of $8.53 and a 12-month high of $22.19. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65.

Analysts Set New Price Targets

Separately, Needham & Company LLC increased their price objective on Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $30.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.